Emergent BioSolutions Inc. EBS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -17.72% | -9.56% | -29.89% | -28.81% | -29.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.72% | -9.56% | -29.89% | -28.81% | -29.91% |
| Cost of Revenue | -9.22% | -12.30% | -47.41% | -48.74% | -50.84% |
| Gross Profit | -26.66% | -6.70% | 10.90% | 18.09% | 26.94% |
| SG&A Expenses | -6.08% | -17.62% | -28.35% | -34.18% | -35.19% |
| Depreciation & Amortization | -6.91% | 1.84% | 0.15% | 0.00% | 0.15% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.98% | -12.67% | -39.27% | -41.86% | -44.03% |
| Operating Income | -75.11% | 9.43% | 262.72% | 305.81% | 244.03% |
| Income Before Tax | -326.63% | -176.56% | 105.62% | 157.94% | 162.37% |
| Income Tax Expenses | -31.00% | -39.84% | -82.54% | -36.69% | -23.08% |
| Earnings from Continuing Operations | -443.48% | -226.74% | 93.47% | 127.60% | 136.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -443.48% | -226.74% | 93.47% | 127.60% | 136.35% |
| EBIT | -75.11% | 9.43% | 262.72% | 305.81% | 244.03% |
| EBITDA | -45.51% | 1.67% | 141.75% | 253.15% | 624.75% |
| EPS Basic | -456.60% | -231.68% | 93.33% | 126.18% | 135.32% |
| Normalized Basic EPS | 14.54% | 49.40% | 187.30% | 190.02% | 141.57% |
| EPS Diluted | -492.63% | -244.96% | 89.71% | 122.42% | 131.63% |
| Normalized Diluted EPS | 25.50% | 55.82% | 174.81% | 181.72% | 136.10% |
| Average Basic Shares Outstanding | -4.07% | -3.15% | -1.21% | 0.99% | 2.96% |
| Average Diluted Shares Outstanding | -4.68% | -1.94% | -0.05% | 2.70% | 4.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |